Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age

References

• Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 86;2008:140–146.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Global measles and rubella strategic plan 2012 – 2020 2012 [ accessed 2016 Dec 6]. https://www.unicef.org/immunization/files/Measles_Rubella_StrategicPlan_2012_2020.pdf.
   Google Scholar
• World Health Organisation. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014;89:265–287.
   PubMedGoogle Scholar
• Baxter R, Ray P, Tran TN, Black S, Shinefield HR, Coplan PM, Lewis E, Fireman B, Saddier P. Long-term effectiveness of varicella vaccine: a 14-year, prospective cohort study. Pediatrics. 2013;131:e1389–96. doi:10.1542/peds.2012-3303.
   PubMed Web of Science ®Google Scholar
• Baxter R, Tran TN, Ray P, Lewis E, Fireman B, Black S, Shinefield HR, Coplan PM, Saddier P. Impact of vaccination on the epidemiology of varicella: 1995-2009. Pediatrics. 2014;134:24–30. doi:10.1542/peds.2013-4251.
   PubMed Web of Science ®Google Scholar
• Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52:332–340. doi:10.1093/cid/ciq077.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Varicella vaccination in the European Union 2015. http://ecdc.europa.eu/en/publications/Publications/Varicella-Guidance-2015.pdf.
   Google Scholar
• Ackerson BK, Sy LS, Yao JF, Cheetham CT, Jacobsen SJ. Impact of MMRV combination vaccine on childhood vaccination compliance. Am J Manag Care. 18;2012:e440–5.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Measles-mumps-rubella-varicella combination vaccine (ProQuad): a guide to its use in children in the. E.U. Paediatric Drug. 2015;17:167–174. doi:10.1007/s40272-015-0123-7.
   PubMed Web of Science ®Google Scholar
• Herzog C. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Rev Vaccines. 2014;13:399–415. doi:10.1586/14760584.2014.883285.
   PubMed Web of Science ®Google Scholar
• Ajana F, Sana C, Caulin E. Are there differences in immunogenicity and safety of vaccines according to the injection method?. Med Mal Infect. 2008;38:648–657. doi:10.1016/j.medmal.2008.09.012.
   PubMed Web of Science ®Google Scholar
• Cook IF. Evidence based route of administration of vaccines. Hum Vaccin. 4;2008:67–73.
   PubMed Web of Science ®Google Scholar
• EMA. ProQuad Summary of Product Characteristics (SmPC). 2014. [ accessed 2014 Dec 5].http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000622/human_med_000997.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Klopfer SO, Stek JE, Petrecz M, Reisinger KS, Black SB, Goveia MG, Nicholson O, Gardner JL, Grosso AD, Brown ML, et al. Analysis of safety data in children after receiving two doses of ProQuad® (MMRV). Vaccine. 2014;32:7154–7160. doi:10.1016/j.vaccine.2014.08.067.
   PubMed Web of Science ®Google Scholar
• Knuf M, Zepp F, Meyer CU, Habermehl P, Maurer L, Burow H-M, Behre U, Janssens M, Willems P, Bisanz H, et al. Safety, immunogenicity and immediate pain of intramuscular versus subcutaneous administration of a measles-mumps-rubella-varicella vaccine to children aged 11-21 months. Eur J Pediatr. 2010;169:925–933. doi:10.1007/s00431-010-1142-6.
   PubMed Web of Science ®Google Scholar
• Silber JL, Chan IS, Wang WW, Matthews H, Kuter BJ. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age. Pediatr Infect Dis J. 2007;26:572–576. doi:10.1097/INF.0b013e318060d33d.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Becker T, Gajdos V, Fiquet A, Thomas S, Richard P, Baudin M. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) in infants from 9 months of age. Vaccine. 2012;30:3082–3089. doi:10.1016/j.vaccine.2012.02.062.
   PubMed Web of Science ®Google Scholar
• Gillet Y, Habermehl P, Thomas S, Eymin C, Fiquet A. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RVAX PRO) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Med. 2009;7:16. doi:10.1186/1741-7015-7-16.
   PubMed Web of Science ®Google Scholar
• Bernstein HH, Eves K, Campbell K, Black SB, Twiggs JD, Reisinger KS, Conti RM, Flodmark C-E, Rombo L, Klopfer S, et al. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). Pediatrics. 2007;119:e1299–305. doi:10.1542/peds.2006-2283.
   PubMed Web of Science ®Google Scholar
• Diez-Domingo J, Weinke T, de Lomas JG, Meyer CU, Bertrand I, Eymin C, Thomas S, Sadorge C. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged >/=50 years: A randomised non-inferiority clinical trial. Vaccine. 2015;33:789–795. doi:10.1016/j.vaccine.2014.12.024.
   PubMed Web of Science ®Google Scholar
• Leung JH, Hirai HW, Tsoi KK. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. Expert Rev Vaccines. 2015;14:1149–1157. doi:10.1586/14760584.2015.1057572.
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Ackerson BK, Sy LS, Tran TN, Jones TL, Yao JF, Xie F, Cheetham TC, Saddier P. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27:4656–4661. doi:10.1016/j.vaccine.2009.05.056.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Global vaccine action plan 2011-2020. 2013. [ accessed 2017 Jun 22]. http://www.who.int/immunization/global_vaccine_action_plan/en/.
   Google Scholar
• Hammond O, Wang Y, Green T, Antonello J, Kuhn R, Motley C, Stump P, Rich B, Chirmule N, Marchese RD. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol. 2006;78:1679–1687. doi:10.1002/jmv.20754.
   PubMed Web of Science ®Google Scholar
• Shehab ZM, Brunell PA, Cobb E. Epidemiological standardization of a test for susceptibility to mumps. J Infect Dis. 149;1984:810–812.
   PubMed Web of Science ®Google Scholar
• Johnson CD, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR. Antibody persistence afer primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs eleven to thirteen years. Pediatr Infect Dis J. 15;1996:687–692.
   PubMed Web of Science ®Google Scholar
• Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 9;1990:1447–1454.
   PubMed Web of Science ®Google Scholar
• Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 4;1985:213–226.
   PubMed Web of Science ®Google Scholar